Sgambato S, Paolisso G, Passariello N, Varricchio M, D'Onofrio F
Eur J Clin Pharmacol. 1987;32(5):477-80. doi: 10.1007/BF00637673.
Infusion of a therapeutic dose of sparteine sulphate, increased the basal plasma insulin level and lowered plasma glucose. When an intravenous glucose tolerance test was performed with the infusion, the total insulin AUC was significantly larger than in absence of sparteine (2025 vs 1464 microU/ml X min), plasma glucose levels were lower and improved glucose utilization was observed (kg:1.55 vs 1.39%). In the presence of arginine, sparteine sulphate stimulated both beta and alpha cells, increasing both the total insulin (1907 vs 1516 microU/ml X min p less than 0.02) and total glucagon AUCs (7616 +/- 654 vs 6789 +/- 707 pg/ml X min p less than 0.01). Thus, sparteine sulphate increased both basal and nutrient-induced insulin and glucagon secretion in normal man.
输注治疗剂量的硫酸司巴丁可提高基础血浆胰岛素水平并降低血浆葡萄糖水平。当在输注硫酸司巴丁的情况下进行静脉葡萄糖耐量试验时，总的胰岛素曲线下面积（AUC）显著大于未使用硫酸司巴丁时（分别为2025与1464微单位/毫升×分钟），血浆葡萄糖水平更低，且观察到葡萄糖利用率提高（葡萄糖代谢率：1.55% 与1.39%）。在精氨酸存在的情况下，硫酸司巴丁刺激β细胞和α细胞，使总的胰岛素AUC（分别为1907与1516微单位/毫升×分钟，p<0.02）和总的胰高血糖素AUC均增加（分别为7616±654与6789±707皮克/毫升×分钟，p<0.01）。因此，硫酸司巴丁可增加正常人基础状态下以及营养物质诱导的胰岛素和胰高血糖素分泌。
